Compare IXHL & GDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | IXHL | GDL |
|---|---|---|
| Founded | 2001 | 2006 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Investment Managers |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.6M | 94.4M |
| IPO Year | N/A | N/A |
| Metric | IXHL | GDL |
|---|---|---|
| Price | $0.27 | $8.57 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 7.5M | 11.2K |
| Earning Date | 02-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.02% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.08 | $7.65 |
| 52 Week High | $1.95 | $8.13 |
| Indicator | IXHL | GDL |
|---|---|---|
| Relative Strength Index (RSI) | 35.13 | 52.65 |
| Support Level | $0.25 | $8.24 |
| Resistance Level | $0.30 | $8.60 |
| Average True Range (ATR) | 0.02 | 0.10 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 24.97 | 69.75 |
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.